Pulmonary arterial hypertension untreated has a median survival of approximately 2.8 years. So, basically, about half of the patients will succumb to the disease in that time frame.

Pulmonary hypertension (PH) is a complex, progressive, rare disease. 1,2 PH is associated with considerable clinical burden and a high mortality rate. Pulmonary arterial hypertension (PAH) is a ...

And of course, pulmonary arterial hypertension (PAH) itself is a rare disease. Ray, talk a little bit about the difference between PH and PAH in terms of definition.

Investigators provide recent information on the classification, pathophysiology, diagnosis, and treatment of pulmonary arterial hypertension, focusing specifically on its impact on women.

Researchers have found a specific bacterial profile in the gut of people with pulmonary arterial hypertension, a chronic and progressive disease that causes constriction of arteries in the lungs ...

Winrevair, also known as sotatercept-csrk, is a medicine used to treat pulmonary arterial hypertension (PAH), which causes high blood pressure in the arteries that go from your heart to your lungs ...

Mere weeks after earning the FDA’s signoff on new drug Winrevair to treat pulmonary arterial hypertension (PAH), Merck has kicked off an educational campaign around the rare disease. The ...

In October, Merck announced that sotatercept, its first-in-class drug for the treatment of pulmonary arterial hypertension, successfully met the primary endpoint of its phase 3 trial, STELLAR ...

Heather Kauffman's brother died of a rare lung disease called pulmonary arterial hypertension. When she developed symptoms, she joined a clinical trial to help others.

The MHRA has approved sotatercept as a new treatment for pulmonary arterial hypertension.

Merck & Co Inc said on Monday its experimental therapy helped increase exercise capacity in patients with a deadly disease that causes high pressure in blood vessels of the heart and lungs in a ...